Sustained-release methylphenidate for cognitive impairment in HIV-1-infected drug abusers: A pilot study

Christopher H. Van Dyck, Thomas J. McMahon, Marc I. Rosen, Stephanie S. O'Malley, Patrick G. O'Connor, C. Huie Lin, H. Rowland Pearsall, Scott W. Woods, Thomas R. Kosten

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Other investigators have reported clinical improvement from psychostimulant drugs in patients with HIV-1-related cognitive impairment. However, no previous research has substantiated this claim by using a controlled study design. We examined the efficacy of sustained-release methylphenidate (MSR) in a sample of substance abusers with HIV-1-related cognitive impairment. Eight HIV-1-infected methadone patients with impaired neuropsychological test performance participated in an inpatient double-blind placebo-controlled crossover trial of MSR 20-40 mg/day. On a composite neuropsychological measure, patients improved significant from baseline during MSR but not placebo treatment. Nevertheless, MSR performance did not differ significantly from placebo performance. Patients appeared to improve as a function of time, regardless of sequence, with somewhat more improvement during MSR than placebo treatment.

Original languageEnglish (US)
Pages (from-to)29-36
Number of pages8
JournalJournal of Neuropsychiatry and Clinical Neurosciences
Volume9
Issue number1
DOIs
StatePublished - 1997

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Sustained-release methylphenidate for cognitive impairment in HIV-1-infected drug abusers: A pilot study'. Together they form a unique fingerprint.

Cite this